
Sign up to save your podcasts
Or


In Episode 8 of Unpackaged Goods, we unpack the biggest CPG deal of the decade: Kimberly-Clark's $49 billion acquisition of Kenvue (Tylenol, Band-Aid, Neutrogena). Plus, Mid-Day Squares proves you don't need venture capital to scale, announcing plans to triple manufacturing capacity using cash flow and debt.
Then, Daniel from Dirty Gut joins us to discuss:
Other stories this week:
From $49B acquisitions to brands tackling taboo topics, this episode explores the different paths to CPG success - and why the uncomfortable conversations might be the best opportunities.
Listen on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts.
By Jonathan DeeterIn Episode 8 of Unpackaged Goods, we unpack the biggest CPG deal of the decade: Kimberly-Clark's $49 billion acquisition of Kenvue (Tylenol, Band-Aid, Neutrogena). Plus, Mid-Day Squares proves you don't need venture capital to scale, announcing plans to triple manufacturing capacity using cash flow and debt.
Then, Daniel from Dirty Gut joins us to discuss:
Other stories this week:
From $49B acquisitions to brands tackling taboo topics, this episode explores the different paths to CPG success - and why the uncomfortable conversations might be the best opportunities.
Listen on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts.